Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
WU Yaru, ZHAO Yuebin, LIU Shiwei. A Case of Diabetes Mellitus Type 2 Complicated with Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 1009-1015. doi: 10.12290/xhyxzz.2021-0053
Citation: WU Yaru, ZHAO Yuebin, LIU Shiwei. A Case of Diabetes Mellitus Type 2 Complicated with Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 1009-1015. doi: 10.12290/xhyxzz.2021-0053

A Case of Diabetes Mellitus Type 2 Complicated with Malignant Melanoma Misdiagnosed as Diabetic Foot Ulcer

doi: 10.12290/xhyxzz.2021-0053
Funds:

Key Research and Development (R & D) Projects of Shanxi Province 201803D31133

Shanxi Scholarship Council of China 2020-180

Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province 20200032

More Information
  • Corresponding author: LIU Shiwei  Tel: 86-351-5656007, E-mail: lswspring6@aliyun.com
  • Received Date: 2021-01-16
  • Accepted Date: 2021-03-23
  • Publish Date: 2021-11-30
  • Acral malignant melanoma, as the main type of melanoma in China, is commonly seen in plantar lesions. Due to similar clinical manifestation, it is easy to be misdiagnosed as diabetic foot ulcers. We report a case of diabetes mellitus complicated with malignant melanoma, which was misdiagnosed as diabetic ulcer in the right foot, thus delaying treatment. Therefore, when diabetic foot lesions are characterized by atypical ulcers and the foot ulcers remain unhealed, pathological examination should be performed to exclude the possibility of malignant melanoma.
  • loading
  • [1] 中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组. 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0[J]. 中华肿瘤杂志, 2020, 42: 81-93. doi:  10.3760/cma.j.issn.0253-3766.2020.02.001

    Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association. Chinese expert consensus on the surgical treatment of cutaneous / acral melanoma V 1.0[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 81-93. doi:  10.3760/cma.j.issn.0253-3766.2020.02.001
    [2] Gregson CL, Allain TJ. Amelanotic malignant melanoma disguised as a diabetic foot ulcer[J]. Diabet Med, 2004, 21: 924-927. doi:  10.1111/j.1464-5491.2004.01338.x
    [3] Hussin P, Loke SC, Noor FM, et al. Malignant melanoma of the foot in patients with diabetes mellitus--a trap for the unwary[J]. Med J Malaysia, 2012, 67: 422-423. http://www.myjurnal.my/filebank/published_article/17871/MJM_2012_Paisal.pdf
    [4] Tadiparthi S, Panchani S, Iqbal A. Biopsy for malignant melanoma--are we following the guidelines?[J]. Ann R Coll Surg Engl, 2008, 90: 322-325. doi:  10.1308/003588408X285856
    [5] 中华医学会糖尿病学分会, 中华医学会感染病学分会, 中华医学会组织修复与再生分会. 中国糖尿病足防治指南(2019版)(Ⅱ)[J]. 中华糖尿病杂志, 2019, 11: 161-189. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX201911002.htm

    Chinese Diabetes Soiety, Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition) (Ⅱ)[J]. Zhonghua Tangniaobing Zazhi, 2019, 11: 161-189. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYX201911002.htm
    [6] Qi L, Qi X, Xiong H, et al. Type 2 diabetes mellitus and risk of malignant melanoma: a systematic review and meta-analysis of cohort studies[J]. Iran J Public Health, 2014, 43: 857-866. http://ijph.tums.ac.ir/index.php/ijph/article/download/4016/3675
    [7] 王璐宁, 关小宏, 吴石白, 等. 以糖尿病足为表现的足趾恶性黑色素瘤一例[J]. 中国医药, 2013, 8: 878. doi:  10.3760/cma.j.issn.1673-4777.2013.06.063

    Wang LN, Guan XH, Wu SB, et al. A case of toe malignant melanoma characterized by diabetic foot[J]. Zhongguo Yiyao, 2013, 8: 878. doi:  10.3760/cma.j.issn.1673-4777.2013.06.063
    [8] 高小华, 裔华. 1例糖尿病足5年并发黑色素瘤合并下肢丹毒患者的护理[J]. 实用临床医药杂志, 2018, 22: 130-132. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201818039.htm

    Gao XH, Yi H. Nursing care of one patients with diabetic foot of 5 years with melanoma and erysipelas in lower extremities[J]. Shiyong Linchuang Yiyao Zazhi, 2018, 22: 130-132. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL201818039.htm
    [9] 孙丽岩, 王泳. 晚期黑色素瘤误诊糖尿病足1例报告[J]. 武警后勤学院学报(医学版), 2012, 21: 638-640. https://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201208022.htm

    Sun LX, Wang Y. The report of one case of malignant melanoma in advanced stage with early symptom as paronychia which misdiagnosed as diabetic foot and literature review[J]. Wujing Houqin Xueyuan Xuebao (Yixueban), 2012, 21: 638-640. https://www.cnki.com.cn/Article/CJFDTOTAL-WUXB201208022.htm
    [10] 王淑敏, 顾俊义, 顾雪明, 等. 糖尿病足截趾术后残端并发黑色素瘤一例[J]. 中华内分泌代谢杂志, 2016, 32: 956-958. doi:  10.3760/cma.j.issn.1000-6699.2016.11.013

    Wang SM, Gu JY, Gu XM, et al. A case of malignant melanoma occurring in the diabetic foot amputation site[J]. Zhonghua Neifenmi Daixie Zazhi, 2016, 32: 956-958. doi:  10.3760/cma.j.issn.1000-6699.2016.11.013
    [11] 刘东, 伦立德. 血液透析患者恶性黑色素瘤误诊为糖尿病足坏疽1例报道[J]. 中国血液净化, 2007, 6: 687. doi:  10.3969/j.issn.1671-4091.2007.12.016

    Liu D, Lun LD. Malignant melanoma misdiagnosed as diabetic foot gangrene in hemodialysis patients: a case report[J]. Zhongguo Xueye Jinghua, 2007, 6: 687. doi:  10.3969/j.issn.1671-4091.2007.12.016
    [12] Zaidi MS, Hassan A, Ouizi S. Can a diabetic foot be malignant?[J]. J Pak Med Assoc, 2016, 66: 1487-1489. http://www.ncbi.nlm.nih.gov/pubmed/27812075
    [13] Gao W, Chen D, Ran X. Malignant melanoma misdiagnosed as diabetic foot ulcer: A case report[J]. Medicine (Baltimore), 2017, 96: e7541. doi:  10.1097/MD.0000000000007541
    [14] Torres T, Rosmaninho A, Caetano M, et al. Malignant melanoma misdiagnosed as a diabetic foot ulcer[J]. Diabet Med, 2010, 27: 1302-1303. doi:  10.1111/j.1464-5491.2010.03102.x
    [15] Rogers LC, Armstrong DG, Boulton AJ, et al. Malignant melanoma misdiagnosed as a diabetic foot ulcer[J]. Diabetes Care, 2007, 30: 444-445.
    [16] Scarfì F, Galeone M, Bassi A, et al. Melanoma manifesting as a verrucous lesion in the interdigital toe space[J]. Int J Dermatol, 2014, 53: 1125. doi:  10.1111/ijd.12638
    [17] Gencoglan G, Inanir I, Miskioglu M, et al. Acral amelanotic verrucous melanoma: dermoscopic findings[J]. Dermatol Surg, 2011, 37: 107. doi:  10.1111/j.1524-4725.2010.01828.x
    [18] Choi YD, Chun SM, Jin SA, et al. Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses[J]. J Am Acad Dermatol, 2013, 69: 700. doi:  10.1016/j.jaad.2013.06.035
    [19] Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies[J]. Eur J Cancer, 2013, 49: 642-657. doi:  10.1016/j.ejca.2012.08.028
    [20] Antoniadis AG, Petridou ET, Antonopoulos CN, et al. Insulin resistance in relation to melanoma risk[J]. Melanoma Res, 2011, 21: 541-546. doi:  10.1097/CMR.0b013e32834b0eeb
    [21] Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth[J]. Endocr Rev, 2000, 21: 215-244. doi:  10.1210/edrv.21.3.0399
    [22] Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases[J]. Med Hypotheses, 2004, 63: 449-452. doi:  10.1016/j.mehy.2004.02.042
    [23] Sharma SD, Katiyar SK. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin[J]. Toxicol Appl Pharmacol, 2010, 44: 328-335. http://www.cabdirect.org/abstracts/20103135333.html
    [24] Grineva EN, Karonova T, Micheeva E, et al. Vitamin D deficiency is a risk factor for obesity and diabetes type 2 in women at late reproductive age[J]. Aging (Albany NY), 2013, 5: 575-581. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765584/pdf/aging-05-575.pdf
    [25] Li L, Wu B, Liu JY, et al. Vitamin D receptor gene polymorphisms and type 2 diabetes: a meta-analysis[J]. Arch Med Res, 2013, 44: 235-241. doi:  10.1016/j.arcmed.2013.02.002
    [26] Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma[J]. Clin Cancer Res, 2000, 6: 498-504. http://pdfs.semanticscholar.org/5de6/a74f13a60f1b4141b08de1bf4faabe74fc33.pdf
    [27] Wysoczańska-Klaczyńska A, Ślęzak A, Hetman M, et al. The impact of VDR gene polymorphisms on obesity, meta-bolic changes, bone mass disorders and neoplastic processes[J]. Pediatr Endocrinol Diabetes Metab, 2018, 24: 96-105. doi:  10.18544/PEDM-24.02.0108
    [28] CSCO黑色素瘤专家委员会. 中国黑色素瘤诊治指南(2011版)[J]. 临床肿瘤学杂志, 2012, 17: 159-171. doi:  10.3969/j.issn.1009-0460.2012.02.015

    Experts Committee on Malignant Melanoma. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2011 Edition)[J]. Linchuang Zhongliuxue Zazhi, 2012, 17: 159-171. doi:  10.3969/j.issn.1009-0460.2012.02.015
    [29] 陈云, 赵静雯, 唐缨. 肝转移性恶性黑色素瘤超声表现1例[J]. 中国超声医学杂志, 2018, 34: 185-186. doi:  10.3969/j.issn.1002-0101.2018.02.029

    Chen Y, Zhao JW, Tang Y. Ultrasonographic features of metastatic melanoma of the liver: a case report[J]. Zhongguo Chaosheng Yixue Zazhi, 2018, 34: 185-186. doi:  10.3969/j.issn.1002-0101.2018.02.029
    [30] 夏波. 视网膜黑色素瘤肝转移误诊为肝硬化一例[J]. 中外医疗, 2009, 28: 172. https://www.cnki.com.cn/Article/CJFDTOTAL-HZZZ200907141.htm

    Xia B. A case of hepatic metastasis of retinal melanoma misdiagnosed as liver cirrhosis[J]. Zhongwai Yiliao, 2009, 28: 172. https://www.cnki.com.cn/Article/CJFDTOTAL-HZZZ200907141.htm
    [31] Cancer Research UK. Melanoma skin cancer[EB/OL]. (2020-03-25)[2020-05-13]. https://www.cancerresearchuk.org/about-cancer/melanoma/survival.
    [32] Helgadottir H, Rocha Trocoli DrakensjöI, Girnita A. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment[J]. Front Oncol, 2018, 8: 202. doi:  10.3389/fonc.2018.00202
    [33] Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16: 522-530. doi:  10.1016/S1470-2045(15)70122-1
    [34] Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2015, 16: 908-918. doi:  10.1016/S1470-2045(15)00083-2
    [35] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372: 320-330. doi:  10.1056/NEJMoa1412082
    [36] Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet, 2015, 386: 444-451. doi:  10.1016/S0140-6736(15)60898-4
    [37] Karlin NJ, Mangold AR, Amin SB, et al. Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus[J]. Future Sci OA, 2019, 5: FSO368. doi:  10.4155/fsoa-2018-0084
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Article Metrics

    Article views (750) PDF downloads(75) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return